Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC

Orexo Sweden

OX640 is Orexo's nasal epinephrine powder product for the acute treatment of severe allergic reactions including anaphylaxis, based on the company´s proprietary drug delivery platform, AmorphOX®The American Academy of Allergy, Asthma & Immunology (AAAAI) is the largest professional medical organization in the United States devoted to the allergy/immunology specialtyThe AAAAI program committee selected OX640 to be presented at its late breaking oral abstract session.. You can also follow Orexo on X (former Twitter), LinkedIn, and YouTube.

About AmorphOX 

Orexo's proprietary drug delivery platform, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure. 

About AAAAI

AAAAI is the leading membership organization of more than 7,100 allergists, asthma specialists, clinical immunologists, allied health professionals and other professionals with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries and is the go-to resource for patients living with allergies, asthma and immune deficiency disorders.

1 Journal of Allergy and Clinical Immunology, Volume 153, Issue 2, AB367
2 https://www.aaaai.org/about/news/news/2024/epinephrine 

The information was submitted for publication at 8.00 am CET on February 6, 2024. 

The following files are available for download:

https://mb.cision.com/Main/694/3923015/2584044.pdf

Orexo PR_OX640 development results to be presented at the AAAAI conference in DC_Publ Feb. 6 2024

 

 

 

View original content:https://www.prnewswire.co.uk/news-releases/orexos-ox640-development-results-to-be-presented-at-the-2024-aaaai-annual-meeting-in-washington-dc-302054263.html